What Did the Research Discover? This study examined whether adding pembrolizumab (Keytruda), an immune checkpoint inhibitor, to standard chemotherapy before surgery could improve outcomes for patients with early-stage triple-negative breast cancer (TNBC). In this large phase 3 trial, 1,174 patients with stage II or III TNBC were randomly assigned to receive either:...
